Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–130. doi:10.3322/canjclin.56.2.106
   PubMed Web of Science ®Google Scholar
• Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Muenster group report. J Clin Oncol. 2007;25(25):3915–3922. doi:10.1200/JCO.2007.11.0700
   PubMed Web of Science ®Google Scholar
• Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary Central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;0409;20(5):687–694 doi:10.1093/neuonc/nox187, PMID:29036697.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH. WHO classification of tumors of hematopoietic and lymphoid tissues[C]2008.
   Google Scholar
• DeAngelis LM, Iwamoto FM. An update on therapy of primary Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program. 2006;2006(1):311–316. doi:10.1182/asheducation-2006.1.311
   Google Scholar
• Abla O, Weitzman S. Primary Central nervous system lymphoma in children. Neurosurg Focus. 2006;21(5):e8–8. doi:10.3171/foc.2006.21.5.9
   PubMedGoogle Scholar
• O'Neill BP, Decker PA, Tieu C, et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and Middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol. 2013;88(12):997–1000. doi:10.1002/ajh.23551
   PubMed Web of Science ®Google Scholar
• Attarbaschi A, Abla O, Ronceray L, et al. Primary Central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. Blood Adv. 2019;3(24):4291–4297. doi:10.1182/bloodadvances.2019001062
   PubMed Web of Science ®Google Scholar
• Choi SY, Kim NK, Kwon SY, et al. Experience of childhood non-Hodgkin lymphoma with central nervous system involvement at diagnosis. Clin Pediatr Hematol Oncol. 2007;14:183–191.
   Google Scholar
• Abla O, Weitzman S, Blay JY, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma collaborative group (IPCG). Clin Cancer Res. 2011;17(2):346–352. doi:10.1158/1078-0432.CCR-10-1161
   PubMed Web of Science ®Google Scholar
• Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–2743. doi:10.1182/blood-2006-07-036665
   PubMed Web of Science ®Google Scholar
• Barouch SB, Kuruvill J, Tsang RW, et al. Radiotherapy in mantle cell lymphoma: a literature review. Hematol Oncol. 2020;38(3):223–228. doi:10.1002/hon.2708
   PubMed Web of Science ®Google Scholar
• Sinicrope K, Batchelor T. Primary Central nervous system lymphoma. Neurol Clin. 2018;36(3):517–532. doi:10.1016/j.ncl.2018.04.008
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Mori T, Kikuchi A, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the japanese pediatric leukemia/lymphoma study group B-NHL03 study. Pediatr Blood Cancer. 2014;61(7):1215–1221. doi:10.1002/pbc.24975
   PubMed Web of Science ®Google Scholar
• O’Suoji C, Welch JJG, Perkins SL, et al. Rare pediatric non-Hodgkin lymphomas: a report from children’s oncology group study ANHL 04B1. Pediatr Blood Cancer. 2016;63(5):794–800. doi:10.1002/pbc.25881
   PubMed Web of Science ®Google Scholar
• Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216–228. doi:10.1016/S1470-2045(18)30747-2
   PubMed Web of Science ®Google Scholar
• Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhances penetration into Central nervous system lymphomas. J Neurosurg. 1999;91(2):221–230. doi:10.3171/jns.1999.91.2.0221
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227. doi:10.1016/S2352-3026(16)00036-3
   PubMed Web of Science ®Google Scholar
• Williams D, Mori T, Reiter A, et al. Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study. Pediatr Blood Cancer. 2013;60(10):E118–E121. doi:10.1002/pbc.24591
   PubMed Web of Science ®Google Scholar
• Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and adolescents with CNS1 Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol. 2019;185(2):374–377. doi:10.1111/bjh.15520
   PubMed Web of Science ®Google Scholar
• Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102(12):2086–2096. doi:10.1111/bjh.15520
   PubMed Web of Science ®Google Scholar
• Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 2002;58(2):175–178. doi:10.1023/a:1016077907952
   PubMed Web of Science ®Google Scholar
• Sierra Del Rio M, Ricard D, Houillier C, et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neurooncol. 2012;106(1):143–146. doi:10.1007/s11060-011-0649-7
   PubMed Web of Science ®Google Scholar
• Thorer H, Zimmermann M, Makarova O, et al. Primary Central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-lymphoma Berlin-Frankfurt-Mu ̈nster protocols for systemic lymphoma. Haematologica. 2014;99(11):e238–e241. doi:10.3324/haematol.2014.109553
   PubMed Web of Science ®Google Scholar